| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2010PNAS..10717339S |
| P356 | DOI | 10.1073/PNAS.1010026107 |
| P932 | PMC publication ID | 2951442 |
| P698 | PubMed publication ID | 20823220 |
| P5875 | ResearchGate publication ID | 46169953 |
| P50 | author | Alexey Ustinov | Q56446816 |
| Che C Colpitts | Q42320812 | ||
| Richard M. Epand | Q43656907 | ||
| P2093 | author name string | Raquel F Epand | |
| Michael A Joyce | |||
| Vladimir A Korshun | |||
| Luis M Schang | |||
| D Lorne J Tyrrell | |||
| Olga A Valueva | |||
| Mireille R St Vincent | |||
| Nicola L Barsby | |||
| Muhammad Muqadas | |||
| Stanislav A Khramyshev | |||
| P2860 | cites work | Imaging poliovirus entry in live cells | Q21092757 |
| Roscovitine inhibits activation of promoters in herpes simplex virus type 1 genomes independently of promoter-specific factors | Q24562983 | ||
| The broad anti-viral agent glycyrrhizin directly modulates the fluidity of plasma membrane and HIV-1 envelope | Q27472782 | ||
| A broad-spectrum antiviral targeting entry of enveloped viruses | Q27491286 | ||
| Antiviral activity of some 5-arylethynyl 2'-deoxyuridine derivatives | Q44503177 | ||
| The effects of membrane physical properties on the fusion of Sendai virus with human erythrocyte ghosts and liposomes. Analysis of kinetics and extent of fusion. | Q45779760 | ||
| Long-term monitoring of genotypic and phenotypic resistance to T20 in treated patients infected with HIV-1. | Q46863910 | ||
| 5-Arylethynyl-2'-deoxyuridines, compounds active against HSV-1. | Q46981677 | ||
| Fluorescent 5-alkynyl-2'-deoxyuridines: high emission efficiency of a conjugated perylene nucleoside in a DNA duplex. | Q50480385 | ||
| Stalk mechanism of vesicle fusion. Intermixing of aqueous contents. | Q52543060 | ||
| Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort study | Q57180242 | ||
| On the mechanism of inhibition of viral and vesicle membrane fusion by carbobenzoxy-D-phenylalanyl-L-phenylalanylglycine | Q68083584 | ||
| Potent inhibition of viral fusion by the lipophosphoglycan of Leishmania donovani | Q72159549 | ||
| BAR domains as sensors of membrane curvature: the amphiphysin BAR structure | Q27642663 | ||
| Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide | Q27644536 | ||
| Membrane proteins of the endoplasmic reticulum induce high-curvature tubules | Q27939309 | ||
| Progressive ordering with decreasing temperature of the phospholipids of influenza virus | Q28270891 | ||
| Membrane curvature and mechanisms of dynamic cell membrane remodelling | Q29617321 | ||
| How proteins produce cellular membrane curvature | Q29618016 | ||
| Drosophila RNAi screen identifies host genes important for influenza virus replication | Q30370530 | ||
| Statins disrupt CCR5 and RANTES expression levels in CD4(+) T lymphocytes in vitro and preferentially decrease infection of R5 versus X4 HIV-1 | Q33285482 | ||
| Structural intermediates in influenza haemagglutinin-mediated fusion | Q33637934 | ||
| Targeting the glycans of glycoproteins: a novel paradigm for antiviral therapy | Q34005185 | ||
| Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect | Q34022149 | ||
| Observation of a membrane fusion intermediate structure | Q34149361 | ||
| Modulation of membrane curvature by phosphatidic acid and lysophosphatidic acid | Q34186047 | ||
| Membrane hemifusion: crossing a chasm in two leaps | Q34465209 | ||
| Fusion peptides and the mechanism of viral fusion | Q35182242 | ||
| The mechanisms of lipid-protein rearrangements during viral infection | Q35757008 | ||
| Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus | Q35921668 | ||
| Rabies virus-induced membrane fusion pathway | Q36328481 | ||
| The eloquent ape: genes, brains and the evolution of language | Q36348747 | ||
| Herpes simplex viruses in antiviral drug discovery. | Q36447331 | ||
| Five years of progress on cyclin-dependent kinases and other cellular proteins as potential targets for antiviral drugs | Q36716750 | ||
| Initial interaction of herpes simplex virus with cells is binding to heparan sulfate | Q36779935 | ||
| Lipids as modulators of membrane fusion mediated by viral fusion proteins | Q36946651 | ||
| Retroviruses human immunodeficiency virus and murine leukemia virus are enriched in phosphoinositides. | Q36949766 | ||
| Targeting inside-out phosphatidylserine as a therapeutic strategy for viral diseases | Q37002766 | ||
| Systems biology and the host response to viral infection | Q37027151 | ||
| HCV drug discovery aimed at viral eradication | Q37664059 | ||
| Missing-in-metastasis and IRSp53 deform PI(4,5)P2-rich membranes by an inverse BAR domain-like mechanism | Q39734937 | ||
| Membrane Asymmetry | Q39859559 | ||
| Alteration of viral lipid composition by expression of the phospholipid floppase ABCB4 reduces HIV vector infectivity | Q40017939 | ||
| The priorities for antiviral drug resistance surveillance and research | Q40175184 | ||
| Membrane fusion: stalk model revisited | Q40200649 | ||
| Antiviral Chemistry & Chemotherapy's current antiviral agents FactFile 2006 (1st edition). | Q40290727 | ||
| Coupling between lipid shape and membrane curvature. | Q41667094 | ||
| Isolation and characterization of human immunodeficiency virus type 1 resistant to the small-molecule CCR5 antagonist TAK-652. | Q42112291 | ||
| P433 | issue | 40 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 17339-17344 | |
| P577 | publication date | 2010-09-07 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | Rigid amphipathic fusion inhibitors, small molecule antiviral compounds against enveloped viruses | |
| P478 | volume | 107 |
| Q39788993 | 5-(Perylen-3-yl)ethynyl-arabino-uridine (aUY11), an arabino-based rigid amphipathic fusion inhibitor, targets virion envelope lipids to inhibit fusion of influenza virus, hepatitis C virus, and other enveloped viruses |
| Q34036018 | A cutting-edge view on the current state of antiviral drug development |
| Q21089597 | A mechanistic paradigm for broad-spectrum antivirals that target virus-cell fusion |
| Q42220929 | A small molecule inhibits virion attachment to heparan sulfate- or sialic acid-containing glycans |
| Q38675925 | Antiviral Lipopeptide-Cell Membrane Interaction Is Influenced by PEG Linker Length. |
| Q92040505 | Antiviral agents against African swine fever virus |
| Q26800190 | Armand-Frappier Outstanding Student Award--The emerging role of 25-hydroxycholesterol in innate immunity |
| Q34908895 | Broad-spectrum antiviral activity of chebulagic acid and punicalagin against viruses that use glycosaminoglycans for entry |
| Q34805086 | Broad-spectrum antiviral that interferes with de novo pyrimidine biosynthesis |
| Q36010083 | Broad-spectrum antivirals against viral fusion |
| Q28544971 | Characterization of potent fusion inhibitors of influenza virus |
| Q38802500 | Characterization of the inhibitory effect of an extract of Prunella vulgaris on Ebola virus glycoprotein (GP)-mediated virus entry and infection |
| Q36724437 | Cholesterol-Enriched Domain Formation Induced by Viral-Encoded, Membrane-Active Amphipathic Peptide. |
| Q38997064 | Clinically Approved Ion Channel Inhibitors Close Gates for Hepatitis C Virus and Open Doors for Drug Repurposing in Infectious Viral Diseases. |
| Q55497501 | Co-protoporphyrin IX and Sn-protoporphyrin IX inactivate Zika, Chikungunya and other arboviruses by targeting the viral envelope. |
| Q38546746 | Development of Small-Molecule Antivirals for Ebola |
| Q34182884 | Driving a wedge between viral lipids blocks infection |
| Q33810598 | Early and late HIV-1 membrane fusion events are impaired by sphinganine lipidated peptides that target the fusion site. |
| Q34042632 | Ebola virus (EBOV) infection: Therapeutic strategies |
| Q38630012 | Effects of HIV-1 gp41-Derived Virucidal Peptides on Virus-like Lipid Membranes. |
| Q35768114 | Effects of singlet oxygen generated by a broad-spectrum viral fusion inhibitor on membrane nanoarchitecture |
| Q26770817 | Entry inhibitors: New advances in HCV treatment |
| Q37544670 | Evaluation of PD 404,182 as an anti-HIV and anti-herpes simplex virus microbicide |
| Q30244058 | Filovirus proteins for antiviral drug discovery: A structure/function analysis of surface glycoproteins and virus entry |
| Q26852435 | Flaviviruses: braking the entering |
| Q35739094 | Flunarizine prevents hepatitis C virus membrane fusion in a genotype-dependent manner by targeting the potential fusion peptide within E1. |
| Q28828700 | Functional organization of the HIV lipid envelope |
| Q90372130 | Ginkgolic acid inhibits fusion of enveloped viruses |
| Q36866689 | Glycoprotein targeted therapeutics: a new era of anti-herpes simplex virus-1 therapeutics |
| Q30386551 | Hepatitis C virus cell entry: a target for novel antiviral strategies to address limitations of direct acting antivirals. |
| Q35600803 | High-Throughput HIV-Cell Fusion Assay for Discovery of Virus Entry Inhibitors |
| Q27692605 | High-quality 3D structures shine light on antibacterial, anti-biofilm and antiviral activities of human cathelicidin LL-37 and its fragments |
| Q38007145 | Highlights in antiviral drug research: antivirals at the horizon |
| Q30507959 | Inhibition of HIV-1 endocytosis allows lipid mixing at the plasma membrane, but not complete fusion. |
| Q57008156 | Lipidomimetic Compounds Act as HIV-1 Entry Inhibitors by Altering Viral Membrane Structure |
| Q38153910 | Lipids in innate antiviral defense |
| Q95301934 | Materials science approaches in the development of broad-spectrum antiviral therapies |
| Q37359745 | Maturation of the Gag core decreases the stability of retroviral lipid membranes |
| Q90219290 | Membrane Composition Modulates Fusion by Altering Membrane Properties and Fusion Peptide Structure |
| Q35556337 | Membrane-proximal external HIV-1 gp41 motif adapted for destabilizing the highly rigid viral envelope |
| Q38010404 | Model membrane platforms for biomedicine: case study on antiviral drug development. |
| Q38628767 | Nanomedicine for Infectious Disease Applications: Innovation towards Broad-Spectrum Treatment of Viral Infections. |
| Q37015805 | New perspectives for preventing hepatitis C virus liver graft infection |
| Q38238424 | New pharmacological strategies to fight enveloped viruses |
| Q54256710 | Nucleoside analogs as a rich source of antiviral agents active against arthropod-borne flaviviruses. |
| Q34074331 | PD 404,182 is a virocidal small molecule that disrupts hepatitis C virus and human immunodeficiency virus |
| Q57456320 | Pathological processes activated by herpes simplex virus-1 (HSV-1) infection in the cornea |
| Q38953166 | Pathophysiology of Ebola Virus Infection: Current Challenges and Future Hopes |
| Q41139167 | Positive reinforcement for viruses |
| Q47119959 | Pyrene-nucleobase conjugates: synthesis, oligonucleotide binding and confocal bioimaging studies. |
| Q37882865 | Role of lipids in virus replication |
| Q34039661 | Singlet oxygen effects on lipid membranes: implications for the mechanism of action of broad-spectrum viral fusion inhibitors |
| Q59355547 | Surfactin Inhibits Membrane Fusion during Invasion of Epithelial Cells by Enveloped Viruses |
| Q64056978 | Synthetic surfactin analogues have improved anti-PEDV properties |
| Q37824811 | Targeting cell entry of enveloped viruses as an antiviral strategy. |
| Q39491188 | The green tea polyphenol, epigallocatechin-3-gallate, inhibits hepatitis C virus entry |
| Q37547261 | The rigid amphipathic fusion inhibitor dUY11 acts through photosensitization of viruses |
| Q108833939 | The roles of lipids in SARS-CoV-2 viral replication and the host immune response |
| Q92037761 | The seafood Musculus senhousei shows anti-influenza A virus activity by targeting virion envelope lipids |
| Q39117420 | Turmeric curcumin inhibits entry of all hepatitis C virus genotypes into human liver cells |
Search more.